Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Number To Know…23

Executive Summary

Thermo Fisher Scientific's Oncomine Dx Target Test is designed to evaluate simultaneously 23 genes associated with non-small cell lung cancer; it is the first of its kind to be approved by the US regulatory watchdog.

You may also be interested in...



Lilly Gets First Of Its Kind FDA Citation For Trulicity Instagram Post

Promotion does not adequately communicate the diabetes drug’s indication, limits of use and risks, FDA says. It objects to distracting visuals in video and less prominent risk information. Agency had previously relayed its concerns to Lilly about Trulicity promotions.

Unilever Announces Corporate Restructuring Amid Reports Of Activist Investor Influence

Around 1,500 senior and junior management roles will be cut under Unilever’s announced plan to reshape its corporate matrix, the firm reports on 25 January. The news comes a day after reports that activist investor Nelson Peltz of Trian Fund Management has taken a stake in the business.

US FDA Would ‘Overstep’ Authority With Planned OTC Sunscreen Environmental Impact Statement

The Public Access to Sunscreens Coalition suggests the FDA should stay in its regulatory lane or at least await the results of a National Academies of Sciences study before moving forward with an environmental impact statement to the US Environmental Protection Agency regarding certain UV filters under GRASE review reported to harm marine coral.

Topics

UsernamePublicRestriction

Register

MT105070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel